I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions
Trust Response:
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
•
Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 61
•
Abemaciclib + Fulvestrant - 12
•
Alpelisib + Fulvestrant - NIL
•
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide - 36
•
Aromatase Inhibitor as a single agent –
Not prescribed on Trust’s system and so we do not have access to this information.
•
Atezolizumab - <5
•
Capecitabine as a single agent - 6
•
Carboplatin + Paclitaxel - 28
•
Eribulin as a single agent or in combination - <5
•
Everolimus + Exemestane - 6
•
Fulvestrant as a single agent - <5
•
Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 41
•
Palbociclib + Fulvestrant - 14
•
Parp Inhibitors (Olaparib/Talazoparib) - NIL
•
Pembrolizumab - 26
•
Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - <5
•
Ribociclib + Fulvestrant - NIL
•
Sacituzumab Govitecan - <5
•
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 8
•
Transtuzumab deruxtecan - 10
•
Trastuzumab as a single agent or in combination - 92
•
Trastuzumab emtansine - 12
•
Any other active systemic anti-cancer therapy - 18
Q2. If breast cancer is not treated at or within the Trust, where are patients referred?
We do treat Breast cancer at ELHT, the only treatment we do not provide is radiotherapy whereby patients are referred to Lancashire Teaching Hospitals
